Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2007) 14 P12

ECE2007 Poster Presentations (1) (659 abstracts)

Role of soluble Fas-antigen (sFas), interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) in adrenocortical carcinoma patients

Nikolai Kushlinsky , Timur Britvin , Irina Kazantseva & Arian Kalinin

Russian N.N.Blokhin Cancer Research Center of RAMS, Moscow, Russia; M.F.Vladimirsky Moscow Regional Clinical and Research Institute, Moscow, Russia.

The numerous growth factors and cytokines take part in mechanisms of tumor growth and metastasing.

The aim of this study was determination of sFas, IL-6 and VEGF serum levels in 19 patients with adrenal cortical carcinoma (11 women and 8 men aged 21–72 years). The control group comprised 40 practically healthy donors (22 women and 18 men aged 19–70 years). sFas, IL-6 and VEGF before adrenalectomy and in the control were measured by ELISA. Mean IL-6 (4.6 ng/ml) and VEGF (438.7 pg/ml) levels in adrenocortical carcinoma patients were significantly (P=0.004) higher than in the control (IL-6 – 1.3 ng/ml, VEGF – 126.5 pg/ml). There was no difference in serum sFas between patients (2.0 ng/ml) and the control (0.8 ng/ml). sFas, IL-6 and VEGF were markedly elevated in patients with advanced (III-IV) stages of the disease as compared to early (I-II) stages. In patients with nonfunctional adrenal cortical carcinoma, serum level of VEGF (571.9 pg/ml) was significantly (P=0.046) higher than that in patients with Cushing’s syndrome (460.1 pg/ml). No differences in serum sFas and IL-6 levels were revealed between patients with nonfunctional and hormonally-active tumors. Direct correlation was found between VEGF and IL-6 (P=0.56; r=0.009). 5-year overall survival (100%) of patients with serum VEGF less then 300 pg/ml was significantly (P=0.049) higher compared to patients with serum VEGF exceeding 300 pg/ml (34.3%). 5-year overall survival didn’t depend on the pretreatment serum sFas and IL-6 levels.

We suggest that VEGF serum level in adrenal cortical carcinoma patients may be used as a factor of clinical behaviour and prognosis.

Article tools

My recent searches

No recent searches.